Published

Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Chemical reviews
Date: 2024-01-10
Source: PubMed
DOI: 10.1021/acs.chemrev.3c00375
PubMed: 38033123

Authors

Duan W Cao D Wang S Cheng J

Watch author

Derived topics and classifications

psilocybin Depression Pharmacology Mechanism of Action Receptor Pharmacology Aging Clinical Trial Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 4 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Distinguishing 4- vs 5-Hydroxy- N, N -Dimethyltryptamine (Psilocin vs Bufotenine) Using Hydrogen-Deuterium Back-Exchange2026-02-04 Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy2025-12-01 Molecular insights into the modulation of the 5 HT2 A receptor by serotonin, psilocin, and the G protein subunit Gqα2025-03-01 Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.2024-01-10

Related papers

Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-04 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessClinicalTrials.gov · 2023-03-29 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03